PharmaEngine, Inc. (TPEX:4162)

Market Cap	16.24B
Revenue (ttm)	831.92M
Net Income (ttm)	370.14M
Shares Out	143.68M
EPS (ttm)	2.57
PE Ratio	43.97
Forward PE	17.64
Dividend	1.50 (1.33%)
Ex-Dividend Date	Aug 12, 2024

Volume	2,223,462
Average Volume	2,615,545
Open	111.00
Previous Close	110.00
Day's Range	111.00 - 114.00
52-Week Range	74.80 - 123.00
Beta	0.62
RSI	61.59
Earnings Date	Mar 14, 2025

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2023, PharmaEngine's revenue was 767.67 million, an increase of 17.31% compared to the previous year's 654.38 million. Earnings were 274.65 million, a decrease of -13.84%.